$OTLK

Outlook Therapeutics, Inc.

CIK:0001649989|SEC Filings

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Consolidated Statements of Operations - USD ($)	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Consolidated Statements of Operations
Revenues, net	$ 8,700	$ 1,505,322	$ (1,071,694)	$ 1,505,322
Cost of revenues	16,965	439,815	195,918	439,815
Gross profit	(8,265)	1,065,507	(1,267,612)	1,065,507
Operating expenses:
Research and development	3,251,099	7,134,706	11,385,971	21,201,875
Selling, general and administrative	7,550,845	9,679,481	25,667,565	29,610,692
Loss from operations	(10,810,209)	(15,748,680)	(38,321,148)	(49,747,060)
Loss (Gain) on equity method investment	41,013	30,884	124,765	100,588
Interest (income) expense, net	(7)	49,351	(10)	18,972
Loss from change in fair value of promissory notes	1,103,000	2,323,977	5,351,336	5,739,005
Warrant inducement expenses				33,856,814
(Gain) loss from change in fair value of warrant liability	7,036,009	1,999,610	2,989,800	(40,333,145)
(Gain) loss on extinguishment of debt	1,329,048		1,043,448
Net loss before income taxes	(20,319,272)	(20,152,502)	(47,830,487)	(49,129,294)
Income tax expense				2,800
Net loss	$ (20,319,272)	$ (20,152,502)	$ (47,830,487)	$ (49,132,094)
Per share information:
Loss per share of common stock, basic (in dollars per share)	$ (0.15)	$ (0.55)	$ (0.51)	$ (1.6)
Loss per share of common stock, diluted (in dollars per share)	$ (0.15)	$ (0.55)	$ (0.51)	$ (1.6)
Weighted average shares outstanding, basic (in shares)	136,743,333	36,956,582	93,232,060	30,663,988
Weighted average shares outstanding, diluted (in shares)	136,743,333	36,956,582	93,232,060	30,663,988

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended	9 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jun. 30, 2026	Jun. 30, 2026	Jun. 30, 2025
OPERATING ACTIVITIES
Net Loss	$ (20,319,272)	$ (47,830,487)	$ (49,132,094)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization		74,282	87,315
Stock-based compensation		2,430,304	7,077,332
Loss (Gain) from change in fair value of promissory notes	1,103,000	5,351,336	5,739,005
(Gain) loss on extinguishment of debt	1,329,048	1,043,448
Warrant inducement expenses			33,856,814
Loss (Gain) from change in fair value of warrant liability	7,036,009	2,989,800	(40,333,145)
Loss (Gain) on equity method investment	41,013	124,765	100,588
Changes in operating assets and liabilities:
Accounts receivable		(153,360)	(1,751,422)
Inventory		(1,705,126)	(4,126,716)
Prepaid expenses and other current assets		(761,763)	6,171,166
Other assets			(95,246)
Operating lease liabilities		(43,554)	(37,124)
Accounts payable		(3,628,409)	1,635,794
Accrued expenses		(1,668,924)	1,355,493
Net cash used in operating activities		(43,777,688)	(39,452,240)
INVESTING ACTIVITIES
Investment in joint venture		(2,100,000)
Net cash used in investing activities		(2,100,000)
FINANCING ACTIVITIES
Proceeds from the sale of common stock and warrants to purchase common stock, net of issuance costs		47,026,535	17,759,434
Payment of Issuance Costs		1,930,539	448,045
Proceeds from exercise of common stock warrants		4,918,285	16,831,132
Proceeds from debt			33,100,000
Repayment of debt			(33,817,005)
Payment of financing costs		(977,610)
Net cash provided by financing activities		49,036,671	33,425,516
Net increase (decrease) in cash and cash equivalents		3,158,983	(6,026,724)
Cash and cash equivalents at beginning of period		8,083,085	14,927,538
Cash and cash equivalents at end of period	$ 11,242,068	11,242,068	8,900,814
Supplemental schedule of non-cash financing activities:
Convertible promissory note converted into common stock		18,114,784	25,000
Fair value of common stock warrants exercised reclassified from warrant liability to equity			13,262,801
Common stock issuance costs in accounts payable and accrued expenses		243,317
Common stock and warrant issuance costs in accounts payable and accrued expenses			1,378,327
Reclassification of deferred offering costs against ATM proceeds		$ 322,835	$ 19,205

Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Sep. 30, 2025
Current assets:
Cash and cash equivalents	$ 11,242,068	$ 8,083,085
Accounts receivable	1,644,291	1,490,931
Inventory	5,043,530	3,338,404
Prepaid expenses and other current assets	5,238,312	4,476,549
Total current assets	23,168,201	17,388,969
Operating lease right-of-use assets, net	185,183	225,508
Equity method investment	2,527,418	552,183
Other assets	304,048	417,523
Total assets	26,184,850	18,584,183
Current liabilities:
Current portion of unsecured convertible promissory note		29,947,000
Current portion of unsecured promissory note	18,227,000
Current portion of operating lease liabilities	64,016	58,897
Accounts payable	6,807,296	10,192,388
Accrued expenses	3,278,739	5,314,320
Income taxes payable	302,000	302,000
Total current liabilities	28,679,051	45,814,605
Operating lease liabilities	140,128	188,801
Warrant liability	7,758,238	4,768,438
Total liabilities	36,577,417	50,771,844
Commitments and contingencies (Note 8)
Stockholders' deficit:
Preferred stock, par value $0.01 per share: 10,000,000 shares authorized, no shares issued and outstanding
Common stock, par value $0.01 per share; 260,000,000 shares authorized; 187,096,998 and 53,887,233 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively	1,870,971	538,873
Additional paid-in capital	641,276,712	572,983,229
Accumulated deficit	(653,540,250)	(605,709,763)
Total stockholders' deficit	(10,392,567)	(32,187,661)
Total liabilities and stockholders' deficit	$ 26,184,850	$ 18,584,183